Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection.

Détails

ID Serval
serval:BIB_DBA37AE7C4FE
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection.
Périodique
Journal of Hepatology
Auteur(s)
Lange C.M., Moradpour D., Doehring A., Lehr H.A., Müllhaupt B., Bibert S., Bochud P.Y., Antonino A.T., Pascual M., Farnik H., Shi Y., Bechstein W.O., Moench C., Hansmann M.L., Sarrazin C., Lötsch J., Zeuzem S., Hofmann W.P.
ISSN
0168-8278
ISSN-L
1600-0641 (Electronic)
Statut éditorial
Publié
Date de publication
2011
Volume
55
Numéro
2
Pages
322-327
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't Publication Status: ppublish
Résumé
BACKGROUND & AIMS: Recent studies have described a major impact of genetic variations near the IL28B gene on the natural course and outcome of antiviral therapy in chronic hepatitis C. We therefore, aimed to explore the impact of donor and recipient genotypes of these polymorphisms on hepatitis C virus (HCV) liver graft reinfection.
METHODS: Donor and recipient genotypes of IL28B rs12979860C>T single nucleotide polymorphism were determined in 91 patients with HCV liver graft reinfection, 47 of whom were treated with pegylated interferon-α (PEG-IFN-α) and ribavirin. IL28B genetic polymorphisms were correlated with the natural course and treatment outcome of recurrent hepatitis C.
RESULTS: Patients requiring liver transplantation due to end-stage chronic hepatitis C appeared to be selected toward the adverse genotypes rs12979860 CT/TT compared to non-transplanted HCV-infected patients (p=0.046). Patients with the donor genotype rs12979860 CC had higher peak ALT and HCV RNA serum concentrations than those with CT/TT (p=0.04 and 0.06, respectively). No association was observed between ALT/HCV RNA serum concentrations and recipient genotypes (p>0.3). More important, donor IL28B rs12979860 CC vs. CT/TT genotypes were associated with rapid, complete early, and sustained virologic response (RVR, cEVR, SVR) to treatment with PEG-IFN-α and ribavirin (p=0.003, 0.0012, 0.008, respectively), but weaker associations of recipient genotypes with RVR, cEVR, and SVR were observed as well (p=0.0046, 0.115, 0.118, respectively).
CONCLUSIONS: We provide evidence for a dominant, but not exclusive impact of the donor rather than the recipient IL28B genetic background on the natural course and treatment outcome of HCV liver graft reinfection.
Mots-clé
Adult, Aged, Alanine Transaminase/blood, Antiviral Agents/administration & dosage, Female, Genotype, Hepatitis C, Chronic/drug therapy, Hepatitis C, Chronic/genetics, Humans, Interferon-alpha/administration & dosage, Interleukins/genetics, Liver Cirrhosis/etiology, Liver Transplantation/adverse effects, Liver Transplantation/physiology, Male, Middle Aged, Polyethylene Glycols/administration & dosage, Polymorphism, Single Nucleotide, RNA, Viral/blood, Recombinant Proteins/administration & dosage, Recurrence, Ribavirin/administration & dosage, Tissue Donors, Treatment Outcome
Pubmed
Web of science
Création de la notice
21/01/2011 12:50
Dernière modification de la notice
20/08/2019 16:00
Données d'usage